
PCT/CA03/00847


10/517749

Figure 1: Cell Viability of U87 Human Glioma Cells Treated with a Composition Comprising Rh2, aPPT, and aPPD



10/517749

Figure 2: Cell Viability of B16 Mouse Melanoma Cells Treated with a Composition Comprising Rh2, aPPT, and aPPD



PCT/CA03/00847

10/517749

Figure 3: Cell Viability of MCF7 Human Breast Cancer Cells Treated with a Composition Comprising Rh2, aPPT, and aPPD




Figure 4a: Cell Viability of BXCP-3 Pancreatic Cancer Cells Treated with a Composition Comprising Rh2, aPPT, and aPPD






Figure 4b: Cell Viability of CAPAN-1 Pancreatic Cancer Cells Treated with a Composition Comprising Rh2, aPPT, and aPPD





## Rec'd PCT/PTO 13 DEC 2004 10/517749 ART 34 AMDT

Figure 5: In vivo cancer inhibitory effect of various concentrations of Composition #4.

